SIGA Technologies, Inc. SIGA NASDAQ · Healthcare · United States
$2.65 -5.36% -$0.15
Summary
35 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $116.4M against $274.6K.
- It has been profitable 6 years in a row.
What to watch
- It pays out more in dividends than it earns: 6,020% of profit.
- Revenue fell by 5.1% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 1.4 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 265.9 USD for 1 USD of yearly profit. Over the last five years it was 11.2 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 5.4% a year over 5 years. Over the last 3 years it fell by 5.1% a year. Earnings per share fell by 10% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 46 USD
- Research and development 5,165,418 USD
- Sales and administration -5,165,350 USD
- Taxes and other -16 USD
- Net profit 1.4 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 USD
Out of every 100 USD of revenue, 1.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 22.64%
- Paid out of profit
- 6,020%
The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product Sales and Supportive Services 93%
- Research and Development 6.9%
By region
- UNITED STATES 88%
- CANADA 5.8%
- Non-US 5.8%
Product Sales and Supportive Services brings in 93% of revenue.
Segments in detail